Toward clinically applicable biomarkers in bipolar disorder: Focus on BDNF, inflammatory markers, and endothelial function

Current Psychiatry Reports

Volumn 15, Issue 12, 2013, Pages

  Goldstein, Benjamin I ^a,b   Young, L Trevor ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Biomarkers; Bipolar disorder; Brain derived neurotrophic factor; Cardiovascular; Endothelial function; Endothelium; Inflammation; Inflammatory; Neurotrophic

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; AUTACOID; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; DEPRESSION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MANIA; PROTEIN BLOOD LEVEL; VASCULAR ENDOTHELIUM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84887368960     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0425-9     Document Type: Article

References (101)

1. Hlatky MA et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-16.
2. Pepe MS et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-61. (Pubitemid 32717537)
3. Kessler RC et al. National comorbidity survey replication adolescent supplement (NCS-A): III. Concordance of DSM-IV/CIDI diagnoses with clinical reassessments. J Am Acad Child Adolesc Psychiatry. 2009;48:386-99.
4. Merikangas KR et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49:980-9.
5. Osby U et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-50. (Pubitemid 32979302)
6. Goldstein BI et al. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 2009;11:657-62.
7. Fiedorowicz JG et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med. 2009;71:598-606.
8. Frey BN et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatr. 2013;47:321-32. This article provides a comprehensive and broad-scoping review regarding peripheral biomarkers, as well as neurocognitive and neuroimaging intermediate phenotypes. It offers important insights regarding future potential directions for the field.
9. Pfaffenseller B et al. Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev Neurother. 2013;13:827-42. This article comprises an up-to-date and detailed review of the leading classes of peripheral biomarkers in BD. It is clearly written and helpfully organized according to sub-topics.
10. Goldstein BI et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70:1078-90.
11. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res. 2007;41:979-90. (Pubitemid 47301944)
12. Ridker PM et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9. (Pubitemid 27152782)
13. Rao JS et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15:384-92. An important high-impact article demonstrating the relevance of inflammation on a neuropathologic level in BD.
14. Maes M et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29:141-52.
15. Tsai SY et al. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord. 2001;64:185-93. (Pubitemid 32324211)
16. Ortiz-Dominguez A et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9:596-602. (Pubitemid 47365627)
17. Brietzke E et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116:214-7.
18. O'Brien SM et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90:263-7. (Pubitemid 43183536)
19. Dickerson F et al. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:952-5. (Pubitemid 46660310)
20. Tsai S-Y et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 1999;45:989-94. (Pubitemid 29219619)
21. Kim Y-K, Jung H-G, Myint A-M, Kim H, Park S-H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104:91-5. (Pubitemid 350064526)
22. Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 1999;33:335-40. (Pubitemid 29267636)
23. Knijff EM et al. An imbalance in the production of IL-1B and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9:743-53. (Pubitemid 350042410)
24. Liu H-C et al. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150:116-22. (Pubitemid 38481654)
25. Kim Y-K et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004;129:267-72. (Pubitemid 40127539)
26. Cunha AB et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258:300-4.
27. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144:16-27. One of three recent reviews on this topic, which together provide evidence of convergence in the literature, as well as a demonstration that inflammation-related findings in BD are holding up to the tests of time and independent replication.
28. Munkholm K et al. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47:1119-33. One of three recent reviews on this topic, which together provide evidence of convergence in the literature, as well as a demonstration that inflammation-related findings in BD are holding up to the tests of time and independent replication.
29. Modabbernia A et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74:15-25. One of three recent reviews on this topic, which together provide evidence of convergence in the literature, as well as a demonstration that inflammation-related findings in BD are holding up to the tests of time and independent replication.
30. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-27.
31. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10:1089-93. (Pubitemid 47339961)
32. Lommatzsch M et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived neurotrophic functions. Am J Pathol. 1999;155:1183-93. (Pubitemid 29488926)
33. Gielen A et al. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol. 2003;57:493-7. (Pubitemid 36577910)
34. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328:261-4. (Pubitemid 34876661)
35. Pan W et al. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37:1553-61. (Pubitemid 28550429)
36. Klein AB et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14:347-53. This article provides further evidence that BDNF measured in blood is an adequate proxy for BDNF measured in brain tissue, which gives confidence that measuring BDNF in the blood of patients with BD may, indeed, reflect illness activity in the brain.
37. Lang UE et al. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol Psychiatry. 2007;62:530-5. (Pubitemid 47284037)
38. Geller B et al. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry. 2004;161:1698-700. (Pubitemid 39201469)
39. Tang J et al. Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland China. Neurosci Lett. 2008;433:98-102.
40. Matsuo K et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology. 2009;34:1904-13.
41. Frey BN et al. Brain-derived neurotrophic factor val66met polymorphism affects prefrontal energy metabolism in bipolar disorder. Neuroreport. 2007;18:1567-70. (Pubitemid 47476385)
42. Lin P-Y. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett. 2009;466:139-43.
43. de Oliveira GS et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res. 2009;43:1171-4.
44. Fernandes BS et al. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res. 2009;43:1200-4. Similar to recent meta-analyses regarding inflammation, this article provides evidence of convergence in the literature, as well as a demonstration that BDNF-related findings in BD are holding up to the tests of time and independent replication.
45. Machado-Vieira R et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry. 2007;61:142-4. (Pubitemid 46072782)
46. Cunha ABM et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398:215-9. (Pubitemid 43673698)
47. Fernandes BS et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995-1004.
48. Monteleone P et al. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord. 2008;10:95-100.
49. Kauer-Sant'Anna M et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12:447-58.
50. Dias VV et al. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 2009;11:663-71.
51. Tramontina JF et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett. 2009;452:111-3.
52. Kauer-Sant'Anna M et al. Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord. 2007;9 Suppl 1:128-35. (Pubitemid 47399255)
53. Palomino A et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res. 2006;86:321-2. (Pubitemid 44234056)
54. Grande I et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder. J Psychiatr Res. 2012;46:1511-4.
55. Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord. 1987;13:287-92. (Pubitemid 18049394)
56. Groner JA, Joshi M, Bauer JA. Pediatric precursors of adult cardiovascular disease: noninvasive assessment of early vascular changes in children and adolescents. Pediatrics. 2006;118:1683-91. (Pubitemid 46393818)
57. Urbina EM et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension. 2009;54:919-50.
58. Cooper DC et al. Adverse impact of mood on flow-mediated dilation. Psychosom Med. 2010;72:122-7.
59. Lavoie KL et al. Association between clinical depression and endothelial function measured by forearm hyperemic reactivity. Psychosom Med. 2010;72:20-6.
60. Pizzi C et al. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J. 2008;29:1110-7. (Pubitemid 351844893)
61. Wagner JA et al. History of major depressive disorder and endothelial function in postmenopausal women. Psychosom Med. 2006;68:80-6. (Pubitemid 43803219)
62. Hemingway H et al. Social and psychosocial influences on inflammatory markers and vascular function in civil servants (the Whitehall II study). Am J Cardiol. 2003;92:984-7. (Pubitemid 37214817)
63. Rybakowski JK et al. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry. 2006;60:889-91. (Pubitemid 44527889)
64. Broadley AJM et al. Metyrapone improves endothelial dysfunction in patients with treated depression. J Am Coll Cardiol. 2006;48:170-5. (Pubitemid 44202475)
65. Rajagopalan S et al. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol. 2001;88:196-8. (Pubitemid 32607714)
66. Yang EH et al. Relation of depression to coronary endothelial function. Am J Cardiol. 2007;99:1134-6. (Pubitemid 46560455)
67. Fiedorowicz JG et al. Vasculopathy related to manic/hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study. Psychother Psychosom. 2012;81:235-43.
68. Ridker PM et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43. (Pubitemid 30165206)
69. Buckley DI et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med. 2009;151:483-95.
70. Glowinska-Olszewska B, Tolwinska J, Urban M. Relationship between endothelial dysfunction, carotid artery intima media thickness and circulating markers of vascular inflammation in obese hypertensive children and adolescents. J Pediatr Endocrinol. 2007;20:1125-36. (Pubitemid 350148461)
71. Liu M et al. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther. 2009;23:369-76.
72. Dome P et al. Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Mol Psychiatry. 2009;14:523-31.
73. Kermani P, Hempstead B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med. 2007;17:140-3. (Pubitemid 46670025)
74. Kermani P et al. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest. 2005;115:653-63. (Pubitemid 40322239)
75. Ejiri J et al. Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation. 2005;112:2114-20. (Pubitemid 41475804)
76. Manni L et al. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol. 2005;102:169-71. (Pubitemid 40812937)
77. Donovan MJ et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development. 2000;127:4531-40.
78. Nakahashi T et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett. 2000;470:113-7. (Pubitemid 30151080)
79. Li Q et al. Modeling the neurovascular niche: VEGF- and BDNF-mediated cross-talk between neural stem cells and endothelial cells: an in vitro study. J Neurosci Res. 2006;84:1656-68. (Pubitemid 44892600)
80. Zhang XY et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 2004;65:940-7.
81. Kobayashi K et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:658-63. (Pubitemid 40897773)
82. Padmos RC et al. A discriminating messenger RNA Signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008;65:395-407. (Pubitemid 351519889)
83. Pandey GN, et al. Proinflammatory cytokines in the plasma of patients with pediatric bipolar disorder. In: Massachusetts General Hospital Pediatric Bipolar Disorder Conference. Boston, MA.; 2009.
84. Pandey GN et al. Brain-derived neurotrophic factor gene expression in pediatric bipolar disorder: effects of treatment and clinical response. J Am Acad Child Adolesc Psychiatry. 2008;47:1077-85.
85. Goldstein BI et al. Preliminary findings regarding pro-inflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Child Adolesc Psychopharmacol. 2011;21:479-84. This is a small study that, nonetheless, extends findings from adults into BD among adolescence, and in so doing provides some biological support for the continuity and shared biology of adolescent and adult BD.
86. Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
87. Lovell DJ et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763-9. (Pubitemid 30151920)
88. Goldstein BI et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry. 2008;69:1953-9.
89. Jerrell JM, McIntyre RS, Tripathi A. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry. 2010;71:161-8.
90. Evans-Lacko SE et al. Medical comorbidity among youth diagnosed with bipolar disorder in the United States. J Clin Psychiatry. 2009;70:1461-6.
91. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687-700. (Pubitemid 46816822)
92. Correll CU. Elevated cardiovascular risk in patients with bipolar disorder: when does it start and where does it lead?[comment]. J Clin Psychiatry. 2008;69:1948-52.
93. Tomfohr LM et al. Multiwave associations between depressive symptoms and endothelial function in adolescent and young adult females. Psychosom Med. 2011;73:456-61.
94. Dickerson F et al. A combined marker of inflammation in individuals with mania. PLoS One. 2013;8:e73520. Although this study examines different markers of inflammation than those described in most other articles on the topic, it takes the important step of combining multiple markers to enhance predictive capacity.
95. Kapczinski F et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1366-71.
96. Monteggia LM. Toward neurotrophin-based therapeutics. Am J Psychiatry. 2011;168:114-6. This editorial puts forth the vantage that purposefully modifying neurotrophins may be a valuable approach in the coming years.
97. Nery FG et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23:87-94. (Pubitemid 351359580)
98. Muller N et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680-4. (Pubitemid 43989814)
99. Fletcher JM, Hughes RA. Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor. J Pept Sci. 2006;12:515-24.
100. Dickerson F et al. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150:456-9.
101. Barbosa IG et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord. 2012;137:151-5.